We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Emerging therapies in thymic epithelial tumors (Review).
- Authors
Dapergola, Athina; Gomatou, Georgia; Trontzas, Ioannis; Panagiotou, Emmanouil; Dimakakos, Evangelos; Syrigos, Nikolaos; Kotteas, Elias
- Abstract
Thymic epithelial tumors (TETs), including thymomas and thymic carcinomas, are rare malignancies arising from the thymus gland. The optimal management requires a multidisciplinary approach. Standard first-line systemic treatment involves cytotoxic chemotherapeutic regimens; however, alternative options for systemic treatment are required. Current research focuses on the unique profile of immune-related pathogenic mechanisms of TETs, involving an overlap with certain autoimmune phenotypes, as well as on determining the landscape of oncogenic molecular alterations and the role of tumor angiogenesis. The aim of the present review is to summarize the current clinical investigation on immunotherapy and targeted agents in the management of TETs. Regarding immune checkpoint inhibitors, efficacy results are promising in certain subsets of patients; however, caution is required concerning their toxicity. Anti-angiogenic agents, mainly potent small-molecule inhibitors, have demonstrated antitumor activity in TETs, whereas other targeted agents, including KIT inhibitors and epigenetic agents, are associated with encouraging, yet still modest results for unselected populations, in the absence of predictive biomarkers. Future research should focus on identifying predictive biomarkers for patients with TETs, and should implement multicenter collaborations and appropriate clinical trials tailored for rare tumor types.
- Subjects
EPITHELIAL tumors; THYMUS tumors; IMMUNE checkpoint inhibitors; THYMOMA; THYMUS; ANTINEOPLASTIC agents
- Publication
Oncology Letters, 2023, Vol 25, Issue 2, pN.PAG
- ISSN
1792-1074
- Publication type
Article
- DOI
10.3892/ol.2023.13670